For research use only. Not for therapeutic Use.
APD668（Cat No.:I005002）is a selective, small-molecule antagonist of the A2A adenosine receptor, a G-protein coupled receptor involved in regulating several physiological processes, including immune response and neurotransmission. By blocking the A2A receptor, APD668 can modulate inflammatory pathways and has potential therapeutic applications in conditions like autoimmune diseases, Parkinson’s disease, and cancer immunotherapy. It works by reducing the suppressive effects of adenosine on immune cells, thereby enhancing immune response. APD668 has been investigated in clinical trials for its potential to treat disorders where adenosine receptor activity plays a significant role.
| Catalog Number | I005002 |
| CAS Number | 832714-46-2 |
| Molecular Formula | C21H24FN5O5S |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 2.7 nM (EC50) |
| IUPAC Name | propan-2-yl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate |
| InChI | InChI=1S/C21H24FN5O5S/c1-13(2)31-21(28)26-8-6-14(7-9-26)32-20-16-11-25-27(19(16)23-12-24-20)18-5-4-15(10-17(18)22)33(3,29)30/h4-5,10-14H,6-9H2,1-3H3 |
| InChIKey | XTRUQJBVQBUKSQ-UHFFFAOYSA-N |
| SMILES | CC(C)OC(=O)N1CCC(CC1)OC2=NC=NC3=C2C=NN3C4=C(C=C(C=C4)S(=O)(=O)C)F |
| Reference | 1:Eur J Pharmacol. 2017 Apr 15;801:35-45. doi: 10.1016/j.ejphar.2017.02.043. Epub 2017 Mar 6. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.Bahirat UA,Shenoy RR,Goel RN,Nemmani KV, PMID: 28274625 DOI: 10.1016/j.ejphar.2017.02.043 Abstract: G-protein coupled receptor 119 (GPR119) receptor is a rhodopsin-like, class A Gαs-coupled receptor, predominantly expressed in pancreatic islet cells and intestinal entero-endocrine cells. GPR119 has been emerged as a novel therapeutic target for the treatment of dyslipidemia in type 2 diabetes. In this study, we investigated the effect of APD668, a GPR119 agonist alone and in combination with linagliptin, a DPPIV inhibitor on oral fat tolerance test. Our findings demonstrate that APD668, a GPR119 agonist inhibits the intestinal triglyceride absorption after acute fat load in mice. Single dose administration of APD668 increases incretin secretion and enhances total PYY levels in presence of fat load in mice. We found that, the anti-dyslipidemic action of APD668 was reversed in presence of exendin-3 in oral fat tolerance test. In addition, our results showed that exendin-3 (9-39) failed to block the effect of APD668 on gastric emptying indicating that gastric emptying effects of APD668 are indeed mediated through GPR119 receptor dependent mechanism. Combined administration of APD668 and linagliptin significantly increased plasma active GLP-1 levels in-vivo and showed improvement in fat tolerance. However, APD668 failed to show anti-dyslipidemic activity in tyloxapol-induced hyperlipidemia in mice. Furthermore, we investigated the chronic effects of APD668 on hepatic steatosis in high trans-fat diet fed steatohepatitis model in mice. Oral administration of APD668 in HTF diet fed mice ameliorated hepatic endpoints such as plasma ALT, AST, liver weight and steatosis. These findings suggest that GPR119 agonists may represent a promising therapeutic strategy for the treatment of dyslipidemia and non-alcoholic steatohepatitis.Copyright © 2017 Elsevier B.V. All rights reserved. |
